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Introduction
Parkinson’s disease (PD) is a sporadic neurodegenera-
tive disorder of unknown etiology characterized mainly
by the progressive degeneration of dopaminergic neu-
rons of the substantia nigra pars compacta (SNpc) and
depletion of striatal dopamine. Dopaminergic neuronal
death is accompanied by the appearance of Lewy
bodies (LB), intracytoplasmic inclusions immunoreac-
tive for a-synuclein, ubiquitin, 3-nitrotyrosine and neu-
roﬁlament [1,2]. Many of the genetic factors variously
associated with PD, such as a-synuclein mutations and
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Altered dopamine homeostasis is an accepted mechanism in the pathogene-
sis of Parkinson’s disease. a-Synuclein overexpression and impaired dis-
posal contribute to this mechanism. However, biochemical alterations
associated with the interplay of cytosolic dopamine and increased a-synuc-
lein are still unclear. Catecholaminergic SH-SY5Y human neuroblastoma
cells are a suitable model for investigating dopamine toxicity. In the pres-
ent study, we report the proteomic pattern of SH-SY5Y cells overexpress-
ing a-synuclein (1.6-fold induction) after dopamine exposure. Dopamine
itself is able to upregulate a-synuclein expression. However, the effect is
not observed in cells that already overexpress a-synuclein as a consequence
of transfection. The proteomic analysis highlights signiﬁcant changes in 23
proteins linked to speciﬁc cellular processes, such as cytoskeleton structure
and regulation, mitochondrial function, energetic metabolism, protein syn-
thesis, and neuronal plasticity. A bioinformatic network enrichment proce-
dure generates a signiﬁcant model encompassing all proteins and allows us
to enrich functional categories associated with the combination of factors
analyzed in the present study (i.e. dopamine together with a-synuclein). In
particular, the model suggests a potential involvement of the nuclear factor
kappa B pathway that is experimentally conﬁrmed. Indeed, a-synuclein sig-
niﬁcantly reduces nuclear factor kappa B activation, which is completely
quenched by dopamine treatment.
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overexpression, parkin and PTEN-induced putative
kinase 1 loss-of-function and UCHL1 mutation, lead
to an impairment of neuronal dopamine homeostasis
by interfering with the vesicular storage and release
mechanisms. Dopamine auto-oxidation in the cytosol
determines oxidative stress conditions that are magni-
ﬁed by impairment of the antioxidant defense of the
cell, as in the case of DJ-1 or PTEN-induced putative
kinase 1 mutations. Mitochondrial and proteasome
dysfunction and oxidative stress could account for the
selective degeneration of dopaminergic SNpc neurons
and their speciﬁc vulnerability [1–6].
Single point mutations in a-synuclein, as well as
duplication and triplication of the gene, were reported
to be linked with rare familial forms of PD [6].
However, a-synuclein deposition into LB is a general
hallmark of the PD state, suggesting that the accumula-
tion of a-synuclein might cause selective degeneration
of dopaminergic neurons [1,4]. Expression of either
wild-type or mutant protein in different cell lines dem-
onstrated that a-synuclein modulates dopamine toxic-
ity, which was associated with reactive oxygen species
arising from dopamine oxidation [3,4]. Nevertheless,
the normal function of a-synuclein is poorly under-
stood and a-synuclein expressed at low levels appears
to be neuroprotective and anti-apoptotic, indicating a
dual role for this protein [7–9]. Several lines of evidence
suggest that the upregulation of a-synuclein represents
a compensatory mechanism adopt by neurons to pro-
tect themselves from chronic oxidative stress [9,10].
In the present study, we investigate the dopamine
effect on the expression pattern of cellular proteins in
the human catecholaminergic neuroblastoma cell line
SH-SY5Y, overexpressing a-synuclein. A proteomic
analysis is expected to identify cellular alterations
that are associated with dopamine treatment and
modulated by a-synuclein overexpression, without any
a priori hypothesis [4,11,12]. SH-SY5Y cells couple
good dopamine transporter activity with a low activity
of the vesicular monoamine transporter type 2, such
that cytoplasmic dopamine concentration may be
raised by the administration of exogenous dopamine in
the culture medium [7,13–15].
Results
Dopamine increases the expression of
a-synuclein to a threshold
To obtain a cellular model of a-synuclein overexpres-
sion, the human neuroblastoma cell line SH-SY5Y was
stably transfected with the plasmid containing human
a-synuclein cDNA (a-syn). As a control, we used
SH-SY5Y cells stably transfected with the plasmid
containing b-galactosidase cDNA (b-gal). Western blot
analysis revealed a signiﬁcant 1.6-fold increase in
a-synuclein expression in a-syn cells with respect to
b-gal cells (Fig. 1). The optimal concentration of dopa-
mine to be used in the present study (0.250 mm;
70 ± 5% viability after 24 h for both b-gal and a-syn
cells) was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(Fig. S1). Because dopamine upregulates a-synuclein
expression [13], we measured the level of a-synuclein in
a-syn cells with respect to b-gal cells in the presence of
catalase only (cat) or in the presence of catalase and
0.250 mm dopamine for 24 h (DA). Dopamine treat-
ment signiﬁcantly increased the expression of a-synuc-
lein in b-gal control cells but not in a-syn cells that
already overexpress it as a consequence of transfection
(Fig. 1).
Proteomics analysis reveals quantitative changes
in 23 proteins
Proteomic investigations were conducted on b-gal and
a-syn cells treated or not with dopamine, as described
above. Statistical analysis, by two-way analysis of
β-Actin
α-Synuclein
Fig. 1. Relative expression of a-synuclein in b-gal and a-syn cells in
response to dopamine (DA) treatment. Results are indicated as the
fold of induction relative to expression observed in b-gal cells trea-
ted with catalase (cat) (set to 1). Values (density of a-synuclein
bands normalized to b-actin) are the mean ± SE of three indepen-
dent experiments. *P < 0.005 versus b-gal cat cells.
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variance (ANOVA) of silver-stained gel images
revealed 28 spots whose intensity was signiﬁcantly dif-
ferent in at least one of the four groups considered
(Fig. 2). Two groups of spots showing remarkable
changes in the isoform pattern in the four conditions
were easily assigned to glyceraldehyde 3-phosphate
Fig. 2. A representative silver-stained 2-DE gel of proteins extracted from b-gal cells treated with catalase (cat). Qualitative differences are indi-
cated by squares (A: ATP synthase a; B: GAPDH; C: VDAC2), whereas circles indicate spots whose levels change significantly. Insets report the
relative change (i.e. fold of induction) with respect to the reference condition (b-gal, cat or b-gal cat) arbitrarily set to 1. Values are the mean ± SD
of three different gels in four-bar histograms and of six gels in two-bars histograms. NL, nonlinear. For protein identification, see Table 1.
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dehydrogenase and to mitochondrial ATP synthase a
subunit by comparison with 2D electrophoresis (2-DE)
maps available in the SWISS 2D-PAGE database
(http://www.expasy.org). Additionally, 21 differentially
expressed proteins were identiﬁed by LC-MS-MS
(Table 1; for details on protein identiﬁcation, see
Table S1). After dopamine treatment, one spot com-
pletely disappeared (voltage-dependent anion channel
2; VDAC-2) and ten proteins [pyruvate kinase, 60S
acidic ribosomal protein P2 (RPLP2), eukaryotic
initiation factor 5A (eIF5A), parathymosin, L7 ⁄L12,
annexin A2, annexin A5, aldolase A, fascin 1 and
peroxyredoxin 1] displayed quantitative differences,
regardless of whether or not a-synuclein was overex-
pressed (Fig. 2, insets; black versus white bars). Dopa-
mine-responsive proteins were involved in protein
synthesis, energetic metabolism, calcium-dependent
phospholipid binding, cytoskeleton regulation, redox
homeostasis and mitochondrial electrochemical bal-
ance. Regardless of dopamine treatment, overexpres-
sion of a-synuclein signiﬁcantly affected the levels of
four proteins [stathmin 1, glutathione S-transferase
(GST)p, Ran 1 binding protein and C1q binding pro-
tein], related to cell signaling, apoptosis and cytoskele-
ton regulation (Fig. 2, insets; shaded versus white
bars). On the other hand, six proteins were regulated
in a more complex way (Fig. 2, insets; four-bar histo-
grams), in that a-synuclein overexpression modulated
the dopamine effect [proﬁlin 1, enolase 1, RuvB-like 1,
collapsin response mediator protein 4 (CRMP4) and
lamin A ⁄C, mitoﬁlin]. These proteins deal with the
regulation of the cytoskeleton, transcription and
cell growth, signal transduction and mitochondrial
trafﬁcking.
Network enrichment highlights the involvement
of the nuclear factor kappa B (NF-jB) pathway
Experimentally identiﬁed proteins were analyzed in
terms of both interaction network and Gene Ontology
(GO) classiﬁcation enrichment using ppi spider, a net-
work enrichment algorithm based on known protein–
protein physical interactions [16]. Figure 3 shows
signiﬁcant (P < 0.05) network models for proteins
Table 1. Identification of differentially expressed proteins. Protein spots in silver-stained gels were analyzed by ANOVA. DA, proteins that
showed increased (›) or decreased (ﬂ) expression after dopamine treatment; a-syn, proteins that displayed increased (›) or decreased (ﬂ)
expression as a consequence of a-synuclein overexpression; complex, proteins that displayed altered levels as a result of the association of
dopamine treatment with a-synuclein overexpression (Fig. 2, insets).
Protein
Swiss-
Protein ID Mr (kDa)
a pIa
Identified
peptides
Mascot
score
Sequence
coverage (%) F b P b
Observed
change
RPLP2 P05387 11.7 4.42 4 268 53 8.41 0.020 DA ﬂ · 3.9
Parathymosin P20962 11.4 4.14 2 88 22 12.14 0.008 DA ﬂ · 2.3
eIF5A isoform B P63241 16.8 5.08 2 70 7 12.72 0.007 DA ﬂ · 2.1
L7 ⁄ L12, mitochondrial P52815 21.4 5.37 3 140 11 9.28 0.016 DA ﬂ · 1.6
Peroxiredoxin 1 Q06830 22.1 8.27 9 431 45 10.39 0.012 DA › · 1.5
Annexin A5 Q6FHB3 35.9 4.83 13 720 52 6.72 0.032 DA ﬂ · 1.6
Annexin A2 Q8TBV2 38.6 7.57 6 299 20 5.25 0.050 DA › · 1.6
Aldolase A P04075 39.3 8.34 5 210 20 36.86 0.001 DA › · 2.5
Fascin 1 Q16658 54.5 6.84 7 333 16 5.88 0.042 DA › · 2.3
Pyruvate kinase P14618 57.8 7.95 12 521 29 7.22 0.028 DA › · 1.9
VDAC-2 P45880.2 31.4 7.66 6 268 17 –d –d Absent in DA
Stathmin 1 P16949 17.3 5.76 7 305 32 15.24 0.005 a-Syn ﬂ · 1.8
Ran1BP P43487 23.2 5.19 4 206 21 10.38 0.012 a-Syn ﬂ · 1.6
GSTp P09211 23.4 5.43 8 474 43 6.29 0.037 a-Syn › · 2.1
C1qBP Q07021 23.8 4.32 5 306 21 9.81 0.014 a-Syn › · 1.6
Profilin 1 P07737 15.0 8.44 4 170 41 6.92 0.030 Complex
Enolase 1 P06733 47.1 7.01 8 481 24 6.94 0.03 Complex
RuvB-like 1 Q9Y265 50.2 6.02 10 343 28 11.58 0.009 Complex
CRMP4 Q14195 61.9 6.04 2 81 4 13.02 0.007 Complex
Lamin A ⁄C Q5TCJ3 72.2 6.40 11 536 22 10.91 0.011 Complex
Mitofilin, p32 Q16891 83.7 6.08 5 241 9 12.10 0.008 Complex
GAPDH P04406 35.9 8.58 –c –d –d –d –d Change in pattern
ATP synthase a P25705 55.2 8.28 –c –d –d –d –d Change in pattern
a Theoretical values. b F and P refer to ANOVA. c Identified from SWISS 2D-PAGE database. d Not applicable.
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that displayed signiﬁcant changes after dopamine treat-
ment, regardless of a-synuclein overexpression
(Fig. 3A), and for proteins that displayed signiﬁcant
changes as a consequence of a-synuclein overexpres-
sion or as a result of the association of dopamine
treatment with a-synuclein overexpression (Fig. 3B).
The same analysis performed on all identiﬁed proteins
was able to correctly cluster them in the two classes
described above (data not shown). Statistically-signiﬁ-
cant (P < 0.05) functional association with GO classi-
ﬁcations was obtained from ppi spider starting from
the proteins grouped as above (Tables S2 and S3).
In both cases, bioinformatic analysis revealed that
the NF-jB pathway could be involved in determining
the effects of dopamine treatment and a-synuclein
overexpression. Accordingly, we transfected b-gal and
a-syn cells with the pNF-jB-Luc reporter gene and
measured the NF-jB-dependent luciferase activity
(Fig. 4A). The basal activation of NF-jB was signiﬁ-
cantly reduced by 30% in a-syn cells with respect to
b-gal cells, and the expression of the reporter gene in
b-gal and a-syn cells was almost completely quenched
after 24 h of dopamine treatment.
Because HSP70, a stress-inducible chaperonin, is
known to inhibit NF-jB activation [17], we measured
HSP70 levels in b-gal and a-syn cells treated, or not,
with dopamine (0.250 mm, 24 h) by western blotting.
Although HSP70 levels are similar in a-syn and b-gal
cells, dopamine increases HSP70 levels, regardless of
a-synuclein overexpression (Fig. 4B).
The suggestions obtained from enriched GO catego-
ries (Table S3) led us to evaluate apoptotic cell death
in our experimental setting. The basal level of apopto-
tic cells is not signiﬁcantly different in a-syn cells with
respect to b-gal cells (in agreement with cell viability
assays, see above). Dopamine triggers apoptotic cell
death to the same extent in both a-syn and b-gal cells
(Fig. 5). Remarkably, the percentage of necrotic
cells also was not signiﬁcantly affected by a-synuclein
overexpression (Fig. S2).
Discussion
Proteins differentially expressed in this model are
individually linked to PD
Most of the identiﬁed proteins may be linked to differ-
ent pathogenetic mechanisms in PD, either speciﬁc or
associated with generic stress conditions. Higher glyco-
lytic activity is shown by higher aldolase A, enolase 1
and pyruvate kinase levels, together with a lower para-
thymosin level [18]. However, quantitative alterations
of glycolytic enzymes are frequently observed after a
generic stress event [19]. Qualitative variations of ATP
synthase A and glyceraldehyde 3-phosphate dehydro-
genase do not involve signiﬁcant changes in total pro-
tein level, but rather a rearrangement of the isoform
pattern. This ﬁnding could also reﬂect a proteome
adaptation as a response to perturbation of protein
levels caused by stimuli of different origin [20]. In par-
allel, proteins involved in protein synthesis (i.e. eIF5A,
RPLP2 and its mitochondrial paralog L7 ⁄L12) were
less abundant after dopamine treatment, suggesting
attenuated translation at both cytoplasmic and mito-
chondrial levels under cellular stress conditions [21].
Upregulation of peroxyredoxin 1 is in keeping with
increased reactive oxygen species production by dopa-
mine oxidation that activates apoptosis and induces
the synthesis of antioxidants [22].
Alterations in mitochondrial proteins, on the other
hand, are speciﬁcally linked to one of the major patho-
genetic mechanisms of PD [5]. Worthy of note is the
complete disappearance of the VDAC-2 upon dopa-
mine treatment. This porin of the outer mitochondrial
membrane regulates mitochondrial Ca2+ homeostasis
and mitochondrial-dependent cell death, which are
major pathogenetic factors in PD [23,24]. The changes
observed for mitoﬁlin and mitochondrial C1q binding
protein also suggest mitochondrial impairment. Inter-
estingly, mitoﬁlin is covalently modiﬁed by dopamine
oxidation products [25].
A B
Fig. 3. Enriched protein networks. (A)
Proteins that displayed significant changes
after dopamine treatment. (B) Proteins that
displayed significant changes as a
consequence of a-synuclein overexpression
or as a result of the association of dopamine
treatment with a-synuclein overexpression.
Experimentally identified proteins are
indicated by filled squares. Open circles
indicate common interactors as predicted by
PPI SPIDER (P < 0.05).
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Alterations in either cytoskeleton components or
regulatory proteins were suggested to be linked to
early stages of PD pathogenesis [26]. Interestingly, in
our model, dopamine induces an increase of the actin
bundles regulator fascin 1 [27] and discordant changes
of two calcium-dependent, actin-associated proteins
(annexins A2 and A5), both regulating membrane
dynamics, cell migration, proliferation and apoptosis
[28]. Recently, a role for a-synuclein in actin dynamics
has been suggested [29]. Overexpression of a-synuclein
deﬁnitely affects the cytoskeletal proteins necessary for
neuronal differentiation and synaptic plasticity, such as
proﬁlin 1 [30], stathmin 1 [31] and lamin A ⁄C [32].
Lamin levels could also change in response to oxida-
tive stress conditions [33].
GSTp, whose levels are increased in a-syn cells, may
play an important role in modulating the progression
of PD [34], and a GSTp polymorphism is associated
with PD in a Drosophila model expressing mutant
parkin [35]. Moreover, its expression is responsible for
nigral neuron sensitivity in an experimental model of
PD [36] and quantitative changes in its levels were
observed in SNpc specimens of PD patients by prote-
ome analysis [37].
Eventually, three proteins have shed light on the
Wnt ⁄b-catenin pathway and its regulatory kinase gly-
cogen synthase kinase-3b (GSK-3b). Following a Wnt
signal, b-catenin is imported into the nucleus through
RanGTP-dependent transport and activates the tran-
scription of target genes by recruiting other factors
such as the histone acetyltransferase RuvB-like 1
(Tip49 ⁄pontin). In the absence of a Wnt signal, b-cate-
nin is targeted to degradation by phosphorylation by
GSK-3b [38]. Levels of the RAN binding protein 1
were reduced in a-syn cells with respect to b-gal cells
and RuvB-like 1 is upregulated in a-syn cells in the
absence of dopamine. CRMP4, a member of a family
of neuron-enriched proteins that regulate neurite
Fig. 5. Induction of apoptosis. Apoptotic b-gal and a-syn cells are
measured as a percentage of annexin V positive cells in response
to dopamine treatment DA. **P < 0.001 DA versus cat cells.
Values are the mean ± SE of three independent experiments.
A
B
Fig. 4. Activation of the NF-jB pathway. (A) NF-jB activity mea-
sured by luciferase gene reporter assay after 24 h dopamine treat-
ment (DA) relative to b-gal cells treated with catalase (b-gal cat, set
to 1). **P < 0.001 versus b-gal cat cells. ##P < 0.001 versus a-syn
cat cells. (B) Expression of the NF-jB regulator HSP-70 relative to
expression observed in b-gal cat cells (set to 1). *P < 0.005 versus
b-gal cat cells. Values are the mean ± SE of three independent
experiments.
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outgrowth and growth cone dynamics, is signiﬁcantly
reduced in a-syn cells. Interestingly, CRMP4 is also a
substrate of GSK-3b [39]. Such evidence is in keeping
with the recent description of a functional link between
a-synuclein and GSK-3b activation [40].
Validation of proteomic data through an enriched
network model
Although the involvement of most identiﬁed proteins
with PD pathogenesis is an interesting result per se, we
aimed to build a single, representative network that
possibly grouped together all the proteins differentially
expressed. Instead of validating every single protein by
western blotting, we applied a different approach by
searching for known physical interactions between the
identiﬁed proteins, aiming to validate the body of the
results as a whole. Unexpectedly, all proteins were
included in two different networks and proteins
responding to dopamine treatment only segregated
from those showing a response to a-synuclein overex-
pression alone or in combination with dopamine treat-
ment. The network enrichment procedure suggested a
potential involvement of the NF-jB pathway and of
apoptosis regulation. Conﬁrming this suggestion,
we observed experimentally that dopamine quenched
NF-jB activation both in b-gal and a-syn cells similar
to that reported for the PD-related neurotoxin MPP+
[41]. Increased levels of the molecular chaperone
HSP70 observed in response to dopamine could con-
tribute to the inhibition of NF-jB [17]. Because the
upregulation of HSP70 is only observed after dopa-
mine treatment, the inhibition of NF-jB activity by
a-synuclein overexpression should be linked to a differ-
ent pathway (e.g. to the increase of GSK-3b activity),
as was recently suggested [42]. It should be noted,
however, that the NF-jB pathway is less active in all
the experimental conditions where higher levels of
a-synuclein are present, either as a consequence of
transfection or of dopamine treatment (Fig. 1), sug-
gesting that a-synuclein could at least contribute to the
deactivation of this cascade.
Dopamine is known to induce apoptosis [43] and
the results obtained in the present study are in agree-
ment with this ﬁnding (Fig. 5). Although both anti-
apoptotic and pro-apoptotic properties were attributed
to a-synuclein [8,43], we did not observe any signiﬁ-
cant effect as a result of a-synuclein overexpression on
the percentage of apoptotic cells. This ﬁnding suggests
that a 60% increase of the a-synuclein level does not
exert any apoptotic action by itself; rather, it could
represent a threshold value that discriminates protective
from toxic effects [8].
Conclusions
In conclusion, the proteomic analysis reported in the
present study links dopamine toxicity to speciﬁc
cellular processes such as cytoskeleton structure and
regulation, mitochondrial function, energetic metabo-
lism, protein synthesis and neuronal plasticity. From
the consequent network enrichment procedure we
focused on NF-jB activation, a transcription factor
that regulates neuronal survival [44], and experimen-
tally observed its quenching. These aspects are par-
ticularly relevant for an understanding of the
biochemical pathways involved in PD neurodegenera-
tion. Indeed, the triggers leading to the speciﬁc death
of dopaminergic neurons of SNpc, as well as the
proteins altered during the process, are still not well
understood. Most likely, the main players in deter-
mining the sensitivity of dopaminergic neurons are
altered dopamine homeostasis and a-synuclein misre-
gulation. The analysis reported in the present study
highlights the proteome alteration resulting from
these pathogenetic mechanisms. Thus, by combining
an experimental and computational approach, we
completely fulﬁll the expectations for proteomics with
respect to generating new hypotheses. Therefore,
each element arising from the present study could
represent a valuable starting-point for focused inves-
tigations aiming to better understand the key issues
of PD pathogenesis.
Materials and methods
Cells
Human neuroblastoma SH-SY5Y cells were cultured in 5%
CO2 humidiﬁed atmosphere at 37 C in high-glucose
DMEM with 10% fetal bovine serum, 100 UÆmL)1 penicil-
lin, 100 lgÆmL)1 streptomycin and 2 mm l-glutamine. All
cell culture media and reagents were from PAA (Pasching,
Austria).
As previously described [7], SH-SY5Y cells were trans-
fected with the pcDNA-Syn plasmid containing the com-
plete human wild-type a-synuclein coding sequence (amino
acids 1–140) into the mammalian expression vector
pcDNA3.1 (Invitrogen Ltd, Paisley, UK) or with the
pcDNA-b-gal plasmid containing the b-galactosidase cod-
ing sequence as control. a-Synuclein-expressing cells
(a-syn) and control cells (b-gal) were expanded in the
presence of 200 lgÆmL)1 geneticin. The cells rescued after
selection were maintained as lines. Intentionally, cell lines
were not cloned. This avoided working with only a
few clones but, instead, resulted in an ensemble average of
different clones.
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Cell viability
The dopamine effect on cell viability was assessed by the
MTT assay using the Celltiter 96 nonradioactive cell prolif-
eration assay (Promega, Madison, WI, USA) in accordance
with the manufacturer’s instructions. Cells were exposed for
24 h to different dopamine concentrations (0.125–1.00 mm)
in the presence of 700 UÆmL)1 catalase to eliminate aspe-
ciﬁc effects as a result of H2O2 arising from dopamine
auto-oxidation [45]. A570 was monitored with a Universal
Microplate reader Model 550 (Bio-Rad, Hercules, CA,
USA). All experiments were run in triplicate.
2-DE electrophoresis and statistical analysis
a-Syn and b-gal cells treated or not with 0.250 mm dopa-
mine in the presence of catalase for 24 h were collected by
centrifugation, lysed with 200 lL of lysis solution [7 m
urea, 2 m thiourea, 4% (w ⁄ v) CHAPS, 0.5 lL of protease
inhibitor mix] and centrifuged (13000 g for 30 min at
10 C). Proteins were collected in the supernatant and their
concentration was determined using the Bio-Rad Protein
Assay (Bio-Rad). All experiments were run in triplicate. In
this way, three independent samples were obtained for each
condition (a-syn and b-gal cells, regardless of whether or
not they were treated with dopamine).
2-DE was performed according to Go¨rg et al. [46], with
minor modiﬁcations. Samples (approximately 200 lg) were
diluted to 250 lL with a buffer containing 7 m urea, 2 m thio-
urea, 4% CHAPS, 0.5% IPG buffer 3–10, 2 mm tributylphos-
phine and traces of bromophenol blue, and loaded on 13 cm
IPG DryStrips with a nonlinear 3–10 pH gradient by in-gel
rehydration (1 h at 0 V, 10 h at 50 V). Isoelectrofocussing
was performed at 20 C on IPGphor (GE Healthcare, Little
Chalfont, UK) with the schedule: 2 h at 200 V, 2 h linear gra-
dient to 2000 V, 2 h at 2000 V, 1 h of linear gradient to
5000 V, 2 h at 5000 V, 2 h linear gradient to 8000 V and 2 h
and 30 min at 8000 V. IPG strips were then equilibrated for
2 · 30 min in 50 mm Tris-HCl (pH 8.8), 6 m urea, 30% glyc-
erol, 2% SDS and traces of bromophenol blue containing 1%
dithiothreitol for the ﬁrst equilibration step and 2.5%
iodoacetamide for the second one. SDS ⁄PAGE was per-
formed using 13%, 1.5 mm thick separating polyacrylamide
gels without stacking gel, using Hoefer SE 600 system (GE
Healthcare). The second dimension was carried out at 45 mA
per gel at 18 C. Molecular weight marker proteins (11–170
kDa; Fermentas, Burlington, Canada) were used for calibration.
The 12 gels (three for each experimental condition) were
stained according to MS-compatible silver staining method
[47], scanned with an Epson Perfection V750 Pro transmis-
sion scanner (Epson, Nagano, Japan) and analyzed with
imagemaster 2d platinum software, version 5.0 (GE
Healthcare). Spots were detected automatically by the soft-
ware and manually reﬁned; gels were then matched and the
resulting clusters of spots conﬁrmed manually. Unmatched
spots among the experimental groups were considered as
qualitative differences. Synthetic images (‘average gels’)
comprising spots present in all gels of each experimental
condition were built and then compared; spots were quanti-
ﬁed on the basis of their relative volume (spot volume nor-
malized to the sum of the volumes of all the representative
spots) and those that consistently and signiﬁcantly varied
among the different populations were identiﬁed by two-way
ANOVA analysis with a threshold of P £ 0.05 using statis-
tixl software (http://www.statistixl.com). Folds of induc-
tion were calculated with respect to the reference condition
(b-gal, cat or b-gal cat) arbitrarily set to 1. Where one of
the experimental conditions did not affect signiﬁcantly the
protein level, the relative datasets were joined (six values,
two experimental conditions).
LC-MS-MS analysis for protein identification
Silver-stained spots were manually excised and destained
(1 · 10 min 50 lL of K3[Fe(CN)6] 30 mm and Na2S2O3
100 mm; 6 · 10 min 100 lL of deionized water; 1 · 20 min
100 lL of NH4HCO3 200 mm; 1 · 20 min 100 lL of deion-
ized water), dehydrated with acetonitrile (1 · 40 min
100 lL) and then dried at 37 C by vacuum centrifugation.
The gel pieces were then swollen in 10 lL of digestion buf-
fer containing 50 mm NH4HCO3 and 12.5 ngÆlL
)1 modiﬁed
porcine trypsin (sequencing grade; Promega). After 10 min,
30 lL of 50 mm NH4HCO3 were added to the gel pieces
and digestion allowed to proceed at 37 C overnight. The
supernatants were collected and peptides were extracted in
an ultrasonic bath for 10 min [twice: 100 lL of 50% aceto-
nitrile, 50% H2O, 1% formic acid (v ⁄ v); once: 50 lL of
acetonitrile]. All the supernatants were collected in the same
tube, dried by vacuum centrifugation and dissolved in
20 lL of 2% acetonitrile, 0.1% of formic acid in water.
Peptide mixtures were separated by using a nanoﬂow-
HPLC system (series 1200; Technologies Agilent, Santa
Clara, CA, USA). A sample volume of 10 lL was loaded
onto a 2 cm fused silica pre-column (inner diameter 75 lm,
outer diameter 375 lm) at a ﬂow rate of 2 lLÆmin)1.
Peptides were eluted at a ﬂow rate of 200 nLÆmin)1 with a
linear gradient from Solution A (2% acetonitrile; 0.1%
formic acid) to 50% of Solution B (98% acetonitrile; 0.1%
formic acid) in 40 min over the pre-column in-line with a
homemade 15 cm resolving column (inner diameter 75 lm,
outer diameter 375 lm; Zorbax 300-SB C18; Agilent Tech-
nologies). Peptides were eluted directly into a Esquire 6000
Ion Trap mass spectrometer (Bruker-Daltonik, Bremen,
Germany). Capillary voltage was 1.5–2 kV and a dry gas
ﬂow rate of 10 LÆmin)1 was used with a temperature of
230 C. The scan range was 300–1800 m ⁄ z. The tandem
mass spectra were annotated and peak list ﬁles were gener-
ated, commonly referred to as MGF ﬁles, by running
dataanalysis, version 3.2 (Bruker-Daltonik) using default
parameters. Protein identiﬁcation was manually performed
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by searching the National Center for Biotechnology Infor-
mation nonredundant database (NCBInr 20081021; 709593
sequences searched) using mascot ms ⁄ms ion search soft-
ware, version 27 (http://www.matrixscience.com). The
parameters set were: enzyme trypsin, complete carbami-
domethylation of cysteines and partial oxidation of methio-
nines, peptide mass tolerance ±0.9 Da, fragment mass
tolerance ±0.9 Da, missed cleavages 2, species restriction
to mammals. All identiﬁed proteins are human and have a
mascot score greater than 69, corresponding to a statis-
tically signiﬁcant (P < 0.05) conﬁdent identiﬁcation.
Among the positive matches, only protein identiﬁcations
based on at least two different non-overlapping peptide
sequences of more than six amino acids and with a mass
tolerance < 0.9 Da were accepted (Table S1).
Bioinformatics enrichment and network
clustering
Identiﬁed proteins were clustered in two groups. The ﬁrst
one corresponds to proteins that displayed signiﬁcant
changes in their levels after dopamine treatment (‘DA’ in
Table 1). The second one groups together proteins that
show quantitative alterations in response to a-synuclein
overexpression (‘a-Syn’ in Table 1), or that differentially
respond to dopamine exposure as a function of a-synuclein
overexpression (‘Complex’ in Table 1). Lists were fed to ppi
spider (http://mips.helmholtz-muenchen.de/proj/ppispider/)
aiming to determine a statistically signiﬁcant interaction
network, as well as statistically signiﬁcant functional associ-
ation with GO classiﬁcations [16].
Western blotting
Expression of a-synuclein and HSP70 was determined by
western blotting. Proteins (80 lg) were extracted in RIPA
buffer (25 mm Tris-HCl, pH 7.4, 0.15 m NaCl, 0.1% SDS,
1% Triton X-100, 1% sodium deoxycholate), resolved by
SDS ⁄PAGE on a 16% polyacrylamide gel and then trans-
ferred to a poly(vinylidene diﬂuoride) membrane (Roth,
Karlsruhe, Germany) at 25 V for 2 h. The membrane was
incubated with mouse anti-a-synuclein (BD Transduction
Laboratories, Franklin Lakes, NJ, USA), mouse anti-
HSP70 (Zymed Laboratories, San Francisco, CA, USA) or
mouse anti-b-actin (GeneTex, Irvine, CA, USA) monoclo-
nal antibodies diluted 1 : 1000 in 5% nonfat dry milk in
NaCl ⁄Tris-Tween (10 mm Tris HCl, pH 8, 150 mm NaCl,
0.05% Tween 20) for 1.5 h at room temperature. Protein
bands were visualized using a peroxidase-conjugated anti-
mouse IgG secondary antibody (GeneTex) and the ECL
plus western blotting detection system (Millipore, Billerica,
MA, USA). Relative levels of a-synuclein and HSP70 were
calculated by densitometric analysis (imagej software;
http://rsb.info.nih.gov/ij) and normalized to b-actin. All
experiments were run in triplicate.
Apoptosis analysis
The induction of apoptotic cell death was analyzed by ﬂow
cytometry with the Annexin V-FITC apoptosis detection
kit (Becton-Dickinson, Franklin Lakes, NJ, USA). Brieﬂy,
cells were resuspended (1 · 106 cellsÆmL)1) in binding buf-
fer; 1 · 105 cells were incubated with Annexin V-FITC and
propidium iodide for 15 min at room temperature in the
dark. Samples properly diluted were analyzed with a FAC-
SCalibur ﬂow cytometer (Becton-Dickinson) equipped with
a 15 mW, 488 nm, air-cooled argon ion laser. At least
10 000 events were analyzed for each sample and data were
processed using CellQuest software (Becton-Dickinson).
Fluorescent emission of propidium iodide and Annexin
V-FITC were collected through a 575 and a 530 ⁄ 30 band-
pass ﬁlter, respectively. The percentage of apoptotic cells in
each sample was determined based on the fraction of ann-
exin V positive cells. All experiments were run in triplicate.
Transient transfection and luciferase gene
reporter assay
b-Gal and a-syn cells (60% conﬂuent in six-well plates)
were transfected with pNF-jB-Luc plasmid (Stratagene,
Santa Clara, CA, USA) (150 ngÆwell)1) and phRL-CMV,
containing Renilla luciferase cDNA (5 ngÆwell)1), using
Lipofectamine and OptiMEM medium (Invitrogen, Carls-
bad, CA, USA). In pNF-jB-Luc the expression of the ﬁre-
ﬂy luciferase is controlled by a synthetic promoter
containing ﬁve NF-jB binding sites. After 7 h of incuba-
tion, the transfection mixture was replaced with complete
DMEM containing, or not, 0.250 mm dopamine, in the
presence of 700 UÆmL)1 catalase. Cells were harvested after
24 h, lysed and the cell lysates were tested for luciferase
activities by using the Dual-Luciferase reporter assay sys-
tem (Promega) in accordance with the manufacturer’s
instructions. Experiments were performed in duplicate and
repeated three times with almost identical results being
obtained, indicating statistical signiﬁcance. NF-jB-depen-
dent luciferase activity was normalized to the Renilla lucif-
erase activity present in each sample.
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